Idorsia Names Grifols Executive Roland Wandeler as CEO
Event summary
- Roland Wandeler, PhD, appointed CEO of Idorsia Pharmaceuticals effective October 1, 2026.
- Wandeler succeeds Jean-Paul Clozel, MD, who will remain Chairman of the Board.
- Benjamin Limal and Dominique Le Terrier promoted to Executive Committee.
- Begoña Carreño-Gómez appointed Chief Business Development Officer effective November 1, 2026.
The big picture
Idorsia's appointment of Roland Wandeler as CEO underscores its focus on accelerating growth and unlocking the full value of its innovative portfolio. The move comes at a pivotal stage for the company, which is navigating a financial turnaround and seeking to redefine standards of care in key therapeutic areas. Wandeler's extensive experience in both large pharmaceutical organizations and entrepreneurial biotech environments positions him to lead Idorsia through its next phase of growth.
What we're watching
- Execution Risk
- How Wandeler will accelerate growth and deliver lasting impact for patients while creating long-term value for stakeholders.
- Pipeline Strategy
- Whether Idorsia can sustain momentum with its late-stage and emerging pipeline, including QUVIVIQ, TRYVIO/JERAYGO, lucerastat, and a potential multiple sclerosis treatment.
- Commercial Expansion
- The pace at which Idorsia broadens commercial and partnering expertise within the executive leadership team to drive global commercialization strategies.